Brant Delafontaine

Griet Van Lancker (UGent) , Lucas Van Bortel (UGent) , Brant Delafontaine (UGent) , Koen Boussery (UGent) , Eleonora Swart, Abdel Chahbouni, Jan Van Bocxlaer (UGent) and Pieter Colin (UGent)

(2019) CLINICAL PHARMACOLOGY & THERAPEUTICS. 106(1). p.195-203

Add to list

Journal Article
A1
open access

KH176 under development for rare mitochondrial disease : a first in man randomized controlled clinical trial in healthy male volunteers

Saskia Koene, Edwin Spaans, Lucas Van Bortel (UGent) , Griet Van Lancker (UGent) , Brant Delafontaine (UGent) , Fabio Badilini, Julien Beyrath and Jan Smeitink

(2017) ORPHANET JOURNAL OF RARE DISEASES. 12.

Add to list

Checkpoint inhibition : new treatment options in urologic cancer

Daan De Maeseneer (UGent) , Brant Delafontaine (UGent) and Sylvie Rottey (UGent)

(2017) ACTA CLINICA BELGICA. 72(1). p.24-28

Add to list

Virussen in de behandeling van kanker : oncolytische virotherapie

Brant Delafontaine (UGent) , Griet Van Lancker (UGent) , Lucas Van Bortel (UGent) and Sylvie Rottey (UGent)

(2016) TIJDSCHRIFT VOOR GENEESKUNDE. 72(1). p.29-35

Add to list

Evaluation of a Cerebral-Blood-Volume (CBV) pharmaco-MRI (phMRI) assay utilizing low (0.1mg/70kg) and high (0.2mg/70kg) dose buprenorphine infusion and a novel USPIO contrast agent (Ferumoxytol) in healthy human subjects

Richard Baumgartner, Arie Struyk, Jeff Evelhoch, Cynthia Gargano, Francheska Colon Gonzalez, Haiying Liu, Ruben Declercq, Hans Verheyden, Ingeborg Heirman, Hans De Pla (UGent) , et al.

(2015) Proceedings of the International Society of Magnetic Resonance in Medicine. 23.

Academic Bibliography

Brant Delafontaine

Immunotherapeutic targeting and PET imaging of DLL3 in small-cell neuroendocrine prostate cancer

PRECISION : the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment

Safety and immunogenicity of LY3415244, a bispecific antibody against TIM-3 and PD-L1, in patients with advanced solid tumors

An update on the management of metastatic clear-cell renal cell carcinoma : the BSMO expert panel recommendations

Switchability of gabapentin formulations : a randomized trial to assess bioequivalence between Neurontin and Gabasandoz on the individual subject level

KH176 under development for rare mitochondrial disease : a first in man randomized controlled clinical trial in healthy male volunteers

Checkpoint inhibition : new treatment options in urologic cancer

Virussen in de behandeling van kanker : oncolytische virotherapie

Evaluation of a Cerebral-Blood-Volume (CBV) pharmaco-MRI (phMRI) assay utilizing low (0.1mg/70kg) and high (0.2mg/70kg) dose buprenorphine infusion and a novel USPIO contrast agent (Ferumoxytol) in healthy human subjects

Contents

Support

Contact